Published in Cancer Res on November 15, 2002
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest (2004) 4.03
Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int (2011) 2.49
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res (2012) 1.73
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist (2013) 1.54
Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist (2012) 1.50
Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol (2009) 1.40
Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab (2009) 1.29
Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol (2010) 1.27
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci (2011) 1.22
Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future. Int J Clin Oncol (2008) 1.21
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg (2008) 1.15
Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch (2007) 1.14
Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis (2008) 1.10
Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig (2009) 1.09
Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer (2006) 1.05
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (2010) 1.03
Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice. Endocrinology (2011) 1.01
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone (2009) 0.99
Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs (2008) 0.98
Effect of zoledronate on oral wound healing in rats. Clin Cancer Res (2010) 0.98
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol (2004) 0.97
A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J Dent Res (2011) 0.96
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int (2004) 0.94
Dynamic contrast-enhanced MRI in Paget's disease of bone--correlation of regional microcirculation and bone turnover. Eur Radiol (2008) 0.93
Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol Ther (2012) 0.93
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
[Bisphosphonate-associated osteonecrosis of the jaw]. Mund Kiefer Gesichtschir (2006) 0.92
Bone vascularization in normal and disease conditions. Front Endocrinol (Lausanne) (2013) 0.91
Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Investig (2009) 0.90
Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer (2008) 0.90
Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.90
Rat models of bone metastases. Clin Exp Metastasis (2006) 0.90
Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J Cancer Res Clin Oncol (2009) 0.90
Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report. Skeletal Radiol (2012) 0.87
Atypical femoral fractures. Clin Cases Miner Bone Metab (2013) 0.86
Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases. Br J Cancer (2013) 0.86
Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma. J Cancer Res Clin Oncol (2011) 0.85
Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap. Clin Oral Investig (2011) 0.85
Modulation of murine bone marrow-derived CFU-F and CFU-OB by in vivo bisphosphonate and fluoride treatments. Orthod Craniofac Res (2009) 0.83
Definition of bone necrosis by the pathologist. Clin Cases Miner Bone Metab (2007) 0.83
Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer. J Pain Symptom Manage (2008) 0.83
Pathogenesis, management and prevention of atypical femoral fractures. J Bone Metab (2015) 0.83
Angiogenesis and marrow stromal cell fates: roles in bone strength. Osteoporos Int (2003) 0.82
Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. Int J Dent (2014) 0.82
Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med (2012) 0.82
Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid. Clin Oral Investig (2012) 0.81
Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents. Int J Exp Pathol (2013) 0.81
Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab (2015) 0.81
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. Eur J Cancer (2015) 0.80
Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. PLoS One (2012) 0.80
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression? World J Urol (2012) 0.80
In vivo effects of zoledronic acid on oral mucosal epithelial cells. Oral Dis (2010) 0.80
Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78. Int Orthop (2010) 0.80
Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int (2015) 0.79
Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain. Med Oral Patol Oral Cir Bucal (2015) 0.79
Use of zoledronic acid in the treatment of Paget's disease. Ther Clin Risk Manag (2007) 0.78
Dynamic contrast-enhanced MRI for monitoring bisphosphonate therapy in Paget's disease of bone. Skeletal Radiol (2012) 0.78
Effect of bisphosphonates on orthodontic tooth movement-an update. J Clin Diagn Res (2015) 0.78
Phosphatase inhibitors with anti-angiogenic effect in vitro. APMIS (2010) 0.78
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist (2011) 0.78
The evolving role of zoledronic acid in early breast cancer. Onco Targets Ther (2009) 0.77
Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab (2014) 0.77
Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol (2006) 0.77
Biodistribution of Fracture-Targeted GSK3β Inhibitor-Loaded Micelles for Improved Fracture Healing. Biomacromolecules (2015) 0.77
RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects. Eur J Histochem (2015) 0.77
Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy? J Clin Med (2013) 0.76
Decreased risk of breast cancer associated with oral bisphosphonate therapy. Breast Cancer (Dove Med Press) (2012) 0.75
Dental risk factors for osteonecrosis of the jaws: a CONDOR case-control study. Clin Oral Investig (2012) 0.75
Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res (2014) 0.75
Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates. BMJ Case Rep (2012) 0.75
Zoledronate induces autophagic cell death in human umbilical vein endothelial cells via Beclin-1 dependent pathway activation. Mol Med Rep (2016) 0.75
Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clin Exp Metastasis (2015) 0.75
Prevention of bisphosphonates-induced osteonecrosis. Clin Cases Miner Bone Metab (2007) 0.75
Effect of bisphosphonates on the mandibular bone and gingival epithelium of rats without tooth extraction. Exp Ther Med (2016) 0.75
Treatment of bone marrow lesions (bone marrow edema). Bonekey Rep (2015) 0.75
Effects of a low-level diode laser on oral keratinocytes, oral fibroblasts, endothelial cells and osteoblasts incubated with bisphosphonates: An in vitro study. Biomed Rep (2014) 0.75
Hydro-nium (3-oxo-1-phosphono-1,3-dihydro-isobenzofuran-1-yl)phospho-nate. Acta Crystallogr Sect E Struct Rep Online (2009) 0.75
Regulation of VEGF by mevalonate pathway inhibition in breast cancer. J Bone Oncol (2013) 0.75
Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg (2016) 0.75
Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium. Osteoporos Int (2009) 0.75
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2010) 7.70
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. Radiology (2013) 2.47
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest (2004) 2.30
Interference with netrin-1 and tumor cell death in non-small cell lung cancer. J Natl Cancer Inst (2009) 2.16
A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells. EMBO J (2004) 2.05
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J (2002) 1.64
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res (2007) 1.63
The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A (2006) 1.61
Efficacy of the InVance male sling in men with stress urinary incontinence. Eur Urol (2006) 1.58
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst (2007) 1.56
Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res (2011) 1.56
Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res (2007) 1.55
SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res (2003) 1.55
Conservative management of upper urinary tract tumors. Eur Urol (2002) 1.53
Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol (2014) 1.42
Bisphosphonates in cancer therapy. Cancer Lett (2007) 1.36
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev (2011) 1.34
High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res (2011) 1.34
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet (2007) 1.27
Natural history and treatment of bone complications in prostate cancer. Eur Urol (2006) 1.26
Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol (2006) 1.23
Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int (2007) 1.19
The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res (2011) 1.17
Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol (2013) 1.17
Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer (2010) 1.16
In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem (2003) 1.16
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res (2007) 1.15
Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol (2002) 1.15
Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One (2010) 1.12
Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res (2005) 1.10
Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res (2010) 1.09
Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol (2007) 1.08
Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care (2008) 1.07
Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol (2007) 1.06
PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ. Cytokine (2011) 1.05
SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS One (2007) 1.03
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (2010) 1.03
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone (2010) 1.01
Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol (2009) 1.01
Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res (2011) 1.00
Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism. FASEB J (2006) 0.97
Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate (2010) 0.96
Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol (2008) 0.96
Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer (2005) 0.95
Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res (2008) 0.94
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement. Clin Cancer Res (2012) 0.93
Distribution and dynamics of (99m)Tc-pertechnetate uptake in the thyroid and other organs assessed by single-photon emission computed tomography in living mice. Thyroid (2010) 0.91
The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol (2010) 0.90
Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma. Eur Urol (2010) 0.89
Transmigration: a new property of mature multinucleated osteoclasts. J Bone Miner Res (2006) 0.89
Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer (2007) 0.88
TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res (2014) 0.88
Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol Res (2009) 0.87
Long term results of percutaneous treatment of caliceal diverticular calculi. Eur Urol (2002) 0.86
Systemic delivery and quantification of unformulated interfering RNAs in vivo. Curr Top Med Chem (2009) 0.86
The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer (2006) 0.85
Is it possible to model the risk of malignancy of focal abnormalities found at prostate multiparametric MRI? Eur Radiol (2012) 0.85
Urinary PCA3 score predicts prostate cancer multifocality. J Urol (2011) 0.85
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol (2011) 0.85
How accurate is multiparametric MR imaging in evaluation of prostate cancer volume? Radiology (2014) 0.84
Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics. Urology (2009) 0.84
Prognostic variables to predict cancer-related death in incidental renal tumours. BJU Int (2008) 0.84
Positive correlation between PEDF expression levels and macrophage density in the human prostate. Prostate (2012) 0.84
Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors. PLoS One (2012) 0.83
Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies. Expert Rev Anticancer Ther (2010) 0.83
A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. PLoS One (2013) 0.83
Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia (2008) 0.82
Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. J Proteome Res (2012) 0.82
[Urothelial tumors]. Prog Urol (2007) 0.81
A convenient clinically relevant model of human breast cancer bone metastasis. Clin Exp Metastasis (2007) 0.81
Radiofrequency ablation of renal tumors with an expandable multitined electrode: results, complications, and pilot evaluation of cooled pyeloperfusion for collecting system protection. Cardiovasc Intervent Radiol (2008) 0.81
CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers. World J Urol (2014) 0.81
Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies. J Clin Endocrinol Metab (2014) 0.81
Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. Prostate (2013) 0.80
Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence. FASEB J (2011) 0.80
Normalisation to blood activity is required for the accurate quantification of Na/I symporter ectopic expression by SPECT/CT in individual subjects. PLoS One (2012) 0.80
Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. J Biol Chem (2014) 0.79
Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. Int J Cancer (2014) 0.79
[Renal transplantation techniques in children with impaired patency of the inferior vena cava or iliac vein]. Prog Urol (2005) 0.78
Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int (2010) 0.78
[Comparison of open and laparoscopic partial nephrectomy: a French multicentre experience]. Prog Urol (2007) 0.78
[Does tumor angiogenesis play a role in bone metastatic process?]. Rev Med Suisse Romande (2004) 0.77